+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
GLENMARK

Glenmark Pharmaceuticals Share Price

₹2,276.00 +24.7 (1.1%)
26.97% Gain from 52W Low

11 Aug, 2026 3:57 PM (IST)

Glenmark Pharmaceuticals live price: ₹2,276.00. It opened at ₹2,265 vs previous close ₹2,251; intraday high/low: ₹2,291/₹2,245. The 50 & 200 DMA stand at ₹2,234.10/₹2,117.30.

Glenmark Pharmaceuticals Performance

  • Today's Low
  • ₹2,245
  • Today's High
  • ₹2,291
  • 52 Week Low
  • ₹1,793
  • 52 Week High
  • ₹2,474
  • Open Price₹2,265
  • Previous Close₹2,251
  • Volume299,544
  • 50 DMA₹2,234.10
  • 100 DMA₹2,206.50
  • 200 DMA₹2,117.30

Glenmark Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -0.3%
  • Over 3 Month -3.82%
  • Over 6 Month + 16.24%
  • Over 1 Year + 12.7%

Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!

Invest Now

Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 35.7
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 64,234
  • P/B Ratio
  • 6.1
  • Average True Range
  • 55.3
  • EPS
  • 63.7
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 9.1
  • RSI
  • 55.83
  • MFI
  • 51.15

Latest Stock News Updates

Glenmark Pharmaceuticals Ltd - 532296 - Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Intimation of Allotment of shares under the Employee Stock Option Plan 2016

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst / Institutional Investor Meetings

Glenmark Pharmaceuticals Financials

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹2,276.00
+ 24.7 (1.1%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹2,242.20
  • 50 Day
  • ₹2,234.10
  • 100 Day
  • ₹2,206.50
  • 200 Day
  • ₹2,117.30

Resistance and Support

2270.67 Pivot Speed
  • R3 2,342.30
  • R2 2,316.70
  • R1 2,296.30
  • S1 2,250.30
  • S2 2,224.70
  • S3 2,204.30

Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-31 Quarterly Results
2026-05-29 Audited Results & Final Dividend
2026-01-30 Quarterly Results
2025-11-14 Quarterly Results
2025-09-26 Interim Dividend
Date Purpose Remarks
2026-08-31 FINAL Rs.2.50 per share(250%)Final Dividend
2025-10-03 INTERIM Rs.2.50 per share(250%)Interim Dividend
2025-09-15 FINAL Rs.2.50 per share(250%)Final Dividend
View Glenmark Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2003-10-31 Split Stock Split From Rs 10/- per share to Rs 2/-

Glenmark Pharmaceuticals F&O

Glenmark Pharmaceuticals Shareholding Pattern

46.65%
20.89%
16.76%
13.81%
1.88%

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets. View More
  • NSE Symbol
  • GLENMARK
  • BSE Symbol
  • 532296
  • ISIN
  • INE935A01035

Similar Stocks to Glenmark Pharmaceuticals

Glenmark Pharmaceuticals FAQs

Glenmark Pharmaceuticals share price is ₹2,276 As on 12 August, 2026 | 01:00

The Market Cap of Glenmark Pharmaceuticals is ₹64234.3 Cr As on 12 August, 2026 | 01:00

The P/E ratio of Glenmark Pharmaceuticals is 35.7 As on 12 August, 2026 | 01:00

The PB ratio of Glenmark Pharmaceuticals is 6.1 As on 12 August, 2026 | 01:00

The 52 week High & Low of Glenmark Pharmaceuticals is ₹2474/₹1792.6 respectively As on 12 August, 2026 | 01:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23